Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André, +158

Annals of Oncology

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Nadia Harbeck, Priya Rastogi, Miguel Martín, +80

Annals of Oncology

Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial

L. Dirix, István Takács, Petros Nikolinakos, +7

Cancer Research

Breast OncologyImmunologyProgrammed Death-1 ReceptorPathologyImmunoediting +14

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

Javier Cortés, S-B. Kim, W-P. Chung, +17

Annals of Oncology

Breast OncologyLba1 TrastuzumabMedicineImmunologyPathology +7

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

Sara A. Hurvitz, S.-B. Kim, Wei‐Pang Chung, +18

ESMO Open

460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers

Komal Jhaveri, Hyo S. Han, Efrat Dotan, +15

Annals of Oncology

162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

E.P. Hamilton, Charles L. Shapiro, Valentina Boni, +17

Annals of Oncology

Breast OncologyOpen LabelMedicinePathologyPhase Ib Trial +6

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

MN Dickler, JA Perez Fidalgo, IA Mayer, +25

Cancer Research

Breast OncologyGdc-0927 ExposureEstrogen ReceptorGynecologyPharmacotherapy +18

2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity

ML Disis, M.R. Patel, S. Pant, +12

European Journal of Cancer

Refractory Ovarian CancerAnti-pd-l1 AntibodyMedicineGynecologyImmune Checkpoint Inhibitor +6

610O Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6

Manish Patel, E.P. Hamilton, Sarina A. Piha‐Paul, +9

Annals of Oncology